Cargando…
Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
Although human epidermal growth factor receptor 2 (HER2)-positive breast cancer was associated with poor prognosis, it has been changed after the development of trastuzumab. There has been great progress in perioperative HER2-targeting treatment, and investigations of several novel drugs and their c...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218503/ https://www.ncbi.nlm.nih.gov/pubmed/35756967 http://dx.doi.org/10.1177/17588359221106564 |